Sessa Capital’s Celldex Therapeutics CLDX Stock Holding History

Sessa Capital’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-212,000	Closed	-$9.45M	–	42
2022 Q4	$9.45M	Hold	212,000	–	–	0.58%	19
2022 Q3	$5.96M	Hold	212,000	–	–	0.43%	24
2022 Q2	$5.72M	Hold	212,000	–	–	0.31%	23
2022 Q1	$7.22M	Buy	+212,000	New	+$6.78M	0.35%	28

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Sessa Capital's CLDX Position: Q1 2023 in Review

Sessa Capital sold out of Celldex Therapeutics (CLDX) in Q1 2023, closing a stake of 212,000 shares — an estimated $9.45M sold.

Sessa Capital first reported a position in CLDX in Q1 2022 and held it in 4 quarters. The position peaked at $9.45M in Q4 2022. 161 funds tracked by Wall St. Rank hold CLDX as of Q1 2023.

Sessa Capital reported no remaining Celldex Therapeutics position as of Q1 2023 after selling out during the quarter.
Sessa Capital sold 212,000 Celldex Therapeutics shares in Q1 2023, an estimated $9.45M.
Sessa Capital first reported a position in Celldex Therapeutics in Q1 2022 and held it in 4 quarters.
Sessa Capital's Celldex Therapeutics position peaked at $9.45M in Q4 2022.
161 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2023.

Based on Sessa Capital's 13F filing for Q1 2023, filed 15 May 2023.